| 17th Nov 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 14th Nov 2025 11:00 am |
RNS |
Director/PDMR Shareholding |
| 10th Nov 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 6th Nov 2025 7:00 am |
RNS |
9M and Q3 2025 results |
| 3rd Nov 2025 4:00 pm |
RNS |
Result of General Meeting |
| 3rd Nov 2025 3:00 pm |
RNS |
Total Voting Rights |
| 28th Oct 2025 7:05 am |
RNS |
Director Declaration |
| 28th Oct 2025 7:00 am |
RNS |
Koselugo (selumetinib) approved in the EU |
| 22nd Oct 2025 7:00 am |
RNS |
Tezspire Approved in EU for CRSwNP |
| 20th Oct 2025 7:05 am |
RNS |
US FDA Approves Tezspire in CRSwNP |
| 20th Oct 2025 7:00 am |
RNS |
Positive CHMP opinion for subcutaneous Saphnelo |
| 13th Oct 2025 7:00 am |
RNS |
Agreement with US Govt to lower medicine prices |
| 7th Oct 2025 7:00 am |
RNS |
Baxdrostat met primary endpoint in Bax24 Ph3 trial |
| 6th Oct 2025 7:30 am |
RNS |
Datroway improved OS and PFS in TROPION-Breast02 |
| 1st Oct 2025 3:00 pm |
RNS |
Total Voting Rights |
| 29th Sep 2025 7:30 am |
RNS |
Enhertu improved IDFS in early BC in DB-05 |
| 29th Sep 2025 7:00 am |
RNS |
AZN harmonises listing structure |
| 25th Sep 2025 4:30 pm |
RNS |
Director/PDMR Shareholding |
| 22nd Sep 2025 7:05 am |
RNS |
Koselugo recommended for EU approval |
| 22nd Sep 2025 7:00 am |
RNS |
Tezspire Recommended for Approval in EU for CRSwNP |
| 17th Sep 2025 7:05 am |
RNS |
Saphnelo met primary endpoint in TULIP-SC |
| 17th Sep 2025 7:00 am |
RNS |
Update on RESOLUTE Phase III trial |
| 1st Sep 2025 3:00 pm |
RNS |
Total Voting Rights |
| 28th Aug 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 26th Aug 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 21st Aug 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 18th Aug 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 15th Aug 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 12th Aug 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 1st Aug 2025 3:00 pm |
RNS |
Total Voting Rights |
| 29th Jul 2025 7:00 am |
RNS |
H1 and Q2 2025 results |
| 24th Jul 2025 7:00 am |
RNS |
Gefurulimab nanobody met Phase III endpoints |
| 22nd Jul 2025 7:00 am |
RNS |
AstraZeneca plans to invest $50bn in the US |
| 16th Jul 2025 7:00 am |
RNS |
Update on anselamimab in AL amyloidosis |
| 14th Jul 2025 7:00 am |
RNS |
Baxdrostat met primary endpt in BaxHTN PhIII trial |
| 4th Jul 2025 7:00 am |
RNS |
Imfinzi approved in the EU for bladder cancer |
| 1st Jul 2025 3:00 pm |
RNS |
Total Voting Rights |
| 24th Jun 2025 7:00 am |
RNS |
Datroway approved in US for EGFRm lung cancer |
| 17th Jun 2025 11:45 am |
RNS |
Holding(s) in Company |
| 13th Jun 2025 9:30 am |
RNS |
AstraZeneca enters into collaboration with CSPC |
